Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week High on Better-Than-Expected Earnings

Nektar Therapeutics (NASDAQ:NKTR) shares reached a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $77.00 and last traded at $73.6150, with a volume of 441428 shares changing hands. The stock had previously closed at $70.36.

The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.69) by $0.91. The firm had revenue of $21.81 million during the quarter, compared to the consensus estimate of $10.44 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%.

More Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations — Nektar reported an adjusted loss per share of ($1.78) which was materially better than consensus (around ($2.69)/($2.76)), and revenue of $21.81M topped estimates (~$10.44M); these beats are the primary catalyst for the rally. Nektar Press Release
• Neutral Sentiment: Investor updates and cash position — Management held the Q4 call (transcript available) that investors should read for pipeline and commercialization commentary; cash & investments were $245.8M at year‑end (down from $269.1M), leaving runway and burn as items to watch. Earnings Call Transcript
• Negative Sentiment: Heightened litigation risk — Multiple class actions and securities‑fraud investigations were filed/announced by firms (Pomerantz, Rosen, Faruqi, Glancy, Bernstein, Robbins, etc.) alleging issues tied to disclosures from Feb 26, 2025–Dec 15, 2025; lead‑plaintiff deadlines (e.g., May 5, 2026) and potential claims could create legal costs, management distraction and downside risk to the stock despite the earnings beat. Pomerantz Class Action Notice

Analyst Ratings Changes

Several research analysts have commented on the company. Citigroup initiated coverage on Nektar Therapeutics in a report on Wednesday, November 26th. They set a “buy” rating and a $102.00 target price on the stock. BTIG Research increased their price target on Nektar Therapeutics from $118.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. B. Riley Financial restated a “buy” rating and set a $150.00 price objective (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, December 17th. Finally, William Blair raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $126.29.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the sale, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This represents a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the sale, the insider owned 21,354 shares in the company, valued at approximately $761,697.18. The trade was a 15.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 4,470 shares of company stock worth $181,955 over the last three months. 5.25% of the stock is owned by company insiders.

Institutional Trading of Nektar Therapeutics

Several large investors have recently modified their holdings of NKTR. BNP Paribas Financial Markets increased its stake in shares of Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. Deutsche Bank AG grew its holdings in Nektar Therapeutics by 0.8% in the fourth quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock worth $3,837,000 after purchasing an additional 743 shares during the period. Bayforest Capital Ltd grew its holdings in Nektar Therapeutics by 51.3% in the fourth quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 862 shares during the period. FNY Investment Advisers LLC increased its stake in Nektar Therapeutics by 70.6% in the third quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 1,077 shares in the last quarter. Finally, XTX Topco Ltd increased its stake in Nektar Therapeutics by 22.0% in the fourth quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 1,299 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -9.05 and a beta of 1.17. The firm’s fifty day moving average price is $52.90 and its two-hundred day moving average price is $52.74.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.